Open BiologyMolecular BiologyPeer-reviewed journal article
Disruption of TFIIH activities generates a stress gene expression response and reveals possible new targets against cancer
Maritere Urióstegui-ArcosiD, Rodrigo Aguayo‐OrtiziD, María del Pilar Valencia-Morales, Erika Melchy-PéreziD, Yvonne RosensteiniD, Laura Domı́ngueziD, Mario ZuritaiD
Abstract
Disruption of the enzymatic activities of the transcription factor TFIIH by Triptolide (TPL) or THZ1 could be used against cancer. Here, we used an oncogenesis model to compare the effect of TFIIH inhibitors between transformed cells and their progenitors. We report that tumour cells exhibited highly increased sensitivity to TPL or THZ1 and that the combination of both had an additive effect. TPL affects the interaction between XPB and P52, causing a reduction in the levels of XPB, P52, and P8, but not other TFIIH subunits. RNA-Seq and RNAPII-ChIP-Seq experiments showed that although the levels of many transcripts were reduced, the levels of a significant number were increased after TPL treatment, with maintained or increased RNAPII promoter occupancy. A significant number of these genes encode for factors that have been related to tumour growth and metastasis. Some of these genes were also overexpressed in response to THZ1, which depletion enhances the toxicity of TPL and are possible new targets against cancer.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 8
- FWCI
- 0.24
- Field percentile
- 45th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cell-type specific concentration regulation of the basal transcription factor TFIIH
L.-M. Donnio, C. Miquel, … P.-O. Mari·bioRxiv·Apr 18, 2019
- Transcription factor activities enhance markers of drug response in cancer
L. Garcia-Alonso, F. Iorio, … J. Saez-Rodriguez·bioRxiv·Apr 21, 2017
- The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells
V. Slaninova, L. Heron-Milhavet, … A. Djiane·bioRxiv·Mar 17, 2023
- Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers
Marco Jessen, KyungMok Kim, … Björn von Eyß·bioRxiv·Jul 3, 2025
- Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response
Xiaobing Tian, Praveen R. Srinivasan, Wafik S. El‐Deiry·bioRxiv·Sep 23, 2026
- The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells
Kimberly C. Olney, David B. Nyer, … Karmella Ann Haynes·BMC Systems BiologyPeer-reviewed·Sep 25, 2018